WAAW

2. Treatment given before full microbiology results are available
5. reassessing need, dose, route & duration of antimicrobial therapy
12. Has limited microbial coverage to minimise collateral damage and resistance risk
13. Broad-spectrum carbapenem reserved for severe infections
15. RNA virus responsible for significant seasonal respiratory infections
17. Lab-based input essential to confirm pathogens and optimise antimicrobial therapy.

1. Macrolide used for respiratory infections and chlamydia when first-line therapy isn’t appropriate.
3. A macrolide antibiotic used where penicillin allergy exists
4. Switching to narrower spectrum therapy once culture results are known
6. Enteric bacterium commonly associated with UTIs and gastrointestinal disease strains
7. Loss of effectiveness of an anti-infective medicine in a microorganism
8. Enterobacterales genus associated with pneumonia and UTIs
9. Antibiotic commonly used in lower urinary tract infections in primary care
10. Resistant S. aureus strain not susceptible to β-lactams
11. Organisational or system-wide approach to optimising antimicrobial use
14. if suspected, antibiotic therapy should start within 1 hour according to national guidance
16. Term inclusive of antibacterial, antiviral, antifungal and antiparasitic agents